Eversight Partners with LighTopTech to Improve Imaging Modalities for Eye Tissues
Eversight announced a 4-year partnership with LighTopTech that aims to improve imaging modalities for eye tissues in both clinical and research settings.
Financial terms of the deal were not disclosed.
As part of this partnership, Eversight will integrate LighTopTech's dual modality OCX system—combining optical coherence tomography (OCT) with optical coherence microscopy (OCM)—into its research and development initiatives. The optical coherence technology has the potential to become a single imaging modality for detailed corneal tissue analysis.
"The OCX system represents a significant advancement in ocular imaging technology, and we are confident in its potential to improve clinical precision and support vision research," Onkar B. Sawant, PhD, Vice President of Research & Development, Eversight, said in a company news release. "We are pleased to collaborate with LighTopTech to innovate in the field of ophthalmic imaging and advance vision science to prevent, treat and cure blinding eye conditions.”
The integration of the OCX imaging system will enhance corneal tissue evaluations in Eversight’s eye bank operations, confirming that tissue processing meets surgeons' specifications for various cornea surgeries and detecting anomalies that may render the tissue unsuitable for transplantation. Eversight will provide data to LighTopTech to inform OCX software development that could also automate endothelial cell counting, a critical metric for eye banks, among other eye tissue measurements.
The partnership is bolstered by a grant from the Michigan Foundation for Vision Awareness. The funding is instrumental in the acquisition and implementation of the OCX system.
The Eversight Research & Development team will also utilize the high-resolution dual-mode OCX system to capture detailed images of both the anterior and posterior segments of the eye. This will enable Eversight to provide diagnostic imaging for researchers studying retinal diseases and help better understand retinal disease to one day help patients with retinal vision loss.
Dr. Canavesi will present on "Dual-Modality Imaging for Cellular Volumetric Evaluation of Donor Corneal and Retinal Tissues" at the 2024 Eye Bank Association of America (EBAA) annual meeting in Kansas City this week. The presentation will highlight the technological advancements and the anticipated impact of enhanced imaging modalities and software on the field of eye and vision research resulting from a collaboration between Eversight and LighTopTech.
For more information about Eversight Research & Development, visit eversightvision.org/research.